🇺🇸 FDA
Patent

US 9878031

Compositions, methods of administration and uses for trivalent dengue virus formulations

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 9878031 (Compositions, methods of administration and uses for trivalent dengue virus formulations) held by Takeda Vaccines, Inc. expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Vaccines, Inc.
Grant date
Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12